SciClone Pharmaceuticals Story

SciClone Pharmaceuticals -- USA Stock  

USD 11.15  0.00  0.00%

Macroaxis does not monitor all media channels or aggregates social signals for SciClone Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on SciClone Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for SciClone Pharmaceuticals. Also please take a look at SciClone Pharmaceuticals Hype Analysis, SciClone Pharmaceuticals Correlation and SciClone Pharmaceuticals Performance.
Sale by Hong Zhao of 12500 shares of SciClone Pharmaceuticals
Filed transaction by Sciclone Pharmaceuticals officer. General open market or private sale of non-derivative or derivative security

SciClone Pharmaceuticals Inc insider trading alert for sale of common stock by Hong Zhao, CEO China Operations, on January 3, 2018. This event was filed by Sciclone Pharmaceuticals with SEC on 2017-06-14. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for SciClone Pharmaceuticals

few days ago at http://bangaloreweekly.com 
Oxford Asset Management Has 693000 Holding in SciClone Pharmaceuticals, Inc.
news
BangaloreWeeklyFull coverage
over a month ago at www.macroaxis.com 
Sale by Friedhelm Blobel of 10000 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. General open market or private sale of non-derivative or derivative security
over two months ago at http://weekherald.com 
Disposition of 30000 shares by Richard Hawkins of SciClone Pharmaceuticals subject to Rule 16b-3
news
Filed transaction by Sciclone Pharmaceuticals director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Did you try this?

Run Alpha Finder Now
   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Hide  View All  NextLaunch Alpha Finder

Total Asset

Total Asset Comparative Analysis
  Total Asset 
      SciClone Pharmaceuticals Comparables 
SciClone Pharmaceuticals is currently under evaluation in total asset category among related companies. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Peers

SciClone Pharmaceuticals Related Equities
ABT  0.60 %   
0%
14.0%
MNK  0.36 %   
0%
8.0%
LLY  0.0376 %   
0%
1.0%
MRK  0.48 %   
11.0%
0%
BIO  0.73 %   
17.0%
0%
BMY  1.32 %   
31.0%
0%
ENDP  1.92 %   
45.0%
0%
VRTX  2.33 %   
55.0%
0%
AGN  4.22 %   
100.0%
0%
Also please take a look at SciClone Pharmaceuticals Hype Analysis, SciClone Pharmaceuticals Correlation and SciClone Pharmaceuticals Performance. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.